Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score®(RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)
Keyword(s):
Stage Ii
◽
2018 ◽
Vol 26
(5)
◽
pp. 1227-1235
◽
2019 ◽
2019 ◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 11052-11052
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. e12059-e12059
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. e12013-e12013